-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 31, Hausen's "Erlotinib Hydrochloride Tablets" was approved by the National Medical Products Administration (NMPA), becoming the second domestic generic drug of this variety.
Erlotinib is the first-generation EGFR inhibitor and was approved by the FDA as early as 2004 for the treatment of locally advanced or metastatic NSCLC after at least one chemotherapy failure.
Image source: Insight database (https://db.
At present, in addition to Shanghai Chuangnuo, which is the first imitation approved in China, the Insight database shows that in addition to Hausen, the companies that are currently applying for listing of the drug include Xinlitai, Shandong Kongfu Pharmaceutical, Nanjing Youke, Suzhou Terui, Hunan Kelun and imported generic drugs from India, Dr.
Image source: Insight database (https://db.